HomeCompareHDLS vs MRK

HDLS vs MRK: Dividend Comparison 2026

HDLS yields 7.79% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HDLS wins by $2.7K in total portfolio value
10 years
HDLS
HDLS
● Live price
7.79%
Share price
$25.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.5K
Annual income
$1,275.40
Full HDLS calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — HDLS vs MRK

📍 HDLS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHDLSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HDLS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HDLS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HDLS
Annual income on $10K today (after 15% tax)
$661.99/yr
After 10yr DRIP, annual income (after tax)
$1,084.09/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, HDLS beats the other by $276.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HDLS + MRK for your $10,000?

HDLS: 50%MRK: 50%
100% MRK50/50100% HDLS
Portfolio after 10yr
$32.1K
Annual income
$1,112.85/yr
Blended yield
3.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

HDLS
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HDLS buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHDLSMRK
Forward yield7.79%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$33.5K$30.7K
Annual income after 10y$1,275.40$950.29
Total dividends collected$10.3K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HDLS vs MRK ($10,000, DRIP)

YearHDLS PortfolioHDLS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,479$778.82$11,192$351.54+$287.00HDLS
2$13,118$835.50$12,524$392.70+$594.00HDLS
3$14,928$892.34$14,015$438.65+$913.00HDLS
4$16,922$949.07$15,682$489.96+$1.2KHDLS
5$19,113$1,005.46$17,547$547.23+$1.6KHDLS
6$21,512$1,061.29$19,632$611.16+$1.9KHDLS
7$24,134$1,116.37$21,963$682.53+$2.2KHDLS
8$26,994$1,170.51$24,571$762.18+$2.4KHDLS
9$30,107$1,223.57$27,486$851.08+$2.6KHDLS
10$33,490$1,275.40$30,745$950.29+$2.7KHDLS

HDLS vs MRK: Complete Analysis 2026

HDLSStock

Hub Deals Corp. operates sales platform. The Company offers real estates, luxury items, paintings, jewelry, watches, and yachts.

Full HDLS Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this HDLS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HDLS vs SCHDHDLS vs JEPIHDLS vs OHDLS vs KOHDLS vs MAINHDLS vs JNJHDLS vs ABBVHDLS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.